SWOG clinical trial number
S0701
A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori
Closed
Phase
Accrual
100%
Published
Abbreviated Title
Gastric Cancer Prevention
Activated
06/16/2009
Closed
06/30/2010
Participants
Limited: Institutions Listed on the Title Page
Research committees
Prevention & Epidemiology
Treatment
clarithromycin
metronidazole
bismuth subsalicylate / subcitrate
tetracycline
lansoprazole
amoxicillin
Eligibility Criteria Expand/Collapse
Step 1: Participant must be between 21-65 years of age; be the only member from their household participating; no known allergies to study drugs; no known medical conditions other than H. pylori that requires antibiotic therapy; no known medical conditions that may limit life expectancy;must discontinue use or alcohol, antacids, PPIs; no antibiotics within last 30 days prior to registration; willing to return for follow-up visits; allow submission of blood. Female participants must not be pregnant or nursing. Step 2 critieria: Positive UBT test; negative pregnancy test if applicable.
Publication Information Expand/Collapse
2013
PMid: PMID23403682 | PMC number: PMC3697935
Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG trial S0701)
PMid: PMID23263777 | PMC number: PMC3645498
2012
Treatment of Helicobacter pylori in Latin America [correspondence; authors' reply]
PMid: PMID21777974 | PMC number: PMC3313469
2011
A randomized trial comparing 14-day triple, 10-day sequential, and 5-day concomitant therapy to eradicate Helicobacter pylori in seven Latin American populations
14-day triple, 5-day concomitant, and 10-day sequential therapies for helicobacter pylori infection in seven Latin American sites: a randomised trial [PMID:21777974;PMC3313469]
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/NHLBI-MDS
The National Myelodysplastic Syndromes (MDS) Study
Research Committee(s)
Prevention & Epidemiology
Leukemia
Activated
06/01/2019
Open
Phase